Therefore, we suggest that MYC and AST have a synergetic effect in tumorigenesis, which could indirectly indicate that a higher level of AST is a predictor of poor outcome in DLBCL patients. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.